摘要
目的:探讨生脉活血方对气虚血瘀型慢性心力衰竭合并心房颤动患者的临床治疗效果。方法:选择2023年9月—2024年6月安徽中医药大学附属太和中医院心病科住院部符合标准的气虚血瘀型慢性心力衰竭合并心房颤动的患者,共60例,随机数字表法分为对照组和治疗组,每组各30例,对照组采取标准化常规西药治疗,治疗组在对照组的基础上联合服用生脉活血方,比较2组患者在治疗前后的临床疗效、中医证候疗效、中国文化改良明尼苏达心力衰竭生存质量量表(C-MLHF)、左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、6min步行试验(6MWT)、N末端B型利钠肽原(NT-proBNP)、以及丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、尿酸(UA)、血清肌酐(SCr),并记录治疗期间的不良反应。结果:治疗后,2组患者C-MLHF积分、LVESD、LVEDD、NT-proBNP均较治疗前降低,且治疗组降低更显著(P<0.05);LVEF、6MWT均较治疗前提高,且治疗组明显高于对照组(P<0.05);临床疗效、中医证候疗效比较均具有显著差异,且治疗组疗效显著优于对照组(P<0.05);治疗前后2组患者的ALT、AST、UA、SCr水平组间和组内比较差异均无统计学意义(P>0.05),且在治疗期间均未出现明显不良反应。结论:在常规西药的基础上加服生脉活血方治疗气虚血瘀型慢性心力衰竭合并心房颤动疗效显著,可以很大程度上改善患者的心功能和临床症状,提高患者的预后,且安全性较好。
Objective:To explore the clinical therapeutic effect of Shengmai Huoxue prescription on patients with chronic heart failure of Qi deficiency and blood stasis type combined with atrial fibrillation.Methods:A total of 60 pa-tients with chronic heart failure of Qi deficiency and blood stasis type combined with atrial fibrillation who met the cri-teria and were admitted to the Department of Cardiology of Taihe Hospital Affiliated of Anhui University of Traditional Chinese Medicine from September 2023 to June 2024 were enrolled and randomly divided into a control group and a treatment group,with 30 cases in each group.The control group received standardized conventional Western medicine treatment,while the treatment group received Shengmai Huoxue Decoction in addition to the treatment of the control group.The clinical efficacy,TCM syndrome efficacy,Chinese culture modified Minnesota Life Quality of Heart Fail-ure Scale(C-MLHF),left ventricular ejection fraction(LVEF),left ventricular end-systolic dimension(LVESD),left ventricular end-diastolic dimension(LVEDD),6-min walk test(6MWT),N-terminal pro-B-type natriuretic peptide(NT-proBNP),alanine aminotransferase(ALT),aspartate aminotransferase(AST),uric acid(UA),and serum creatinine(SCr)were compared between the two groups before and after treatment.Adverse reactions during treatment were also recorded.Results:After treatment,C-MLHF scores,LVESD,LVEDD,and NT-proBNP decreased in both groups com-pared with pre-treatment levels,with the decrease being more significant in the treatment group(P<0.05).LVEF and 6MWT increased compared with pre-treatment levels,with those in the treatment group significantly higher than those in the control group(P<0.05).Significant differences were observed in clinical efficacy and TCM syndrome efficacy,with the treatment group showing significantly better efficacy than the control group(P<0.05).There were no statisti-cally significant differences in ALT,AST,UA,and SCr levels between the two groups before and after treatment(P>0.05).No significant adverse reactions were observed during treatment.Conclusion:Shengmai Huoxue Decoction,added to conventional Western medication,is effective in treating chronic heart failure with atrial fibrillation of the Qi deficiency and blood stasis type.It can significantly improve cardiac function and clinical symptoms,enhance prognosis,and has a good safety profile.
作者
林梦迪
姚建斌
汪义可
刘韩
LIN Mengdi;YAO Jianbin;WANG Yike;LIU Han(Taihe Hospital of Traditional Chinese Medicine Affiliated of Anhui University of Chinese Medicine,Anhui Fuyang 236600,China)
出处
《中医药临床杂志》
2025年第9期1792-1797,共6页
Clinical Journal of Traditional Chinese Medicine
基金
2023年度阜阳市卫生健康科研项目(FY2023-060)。
关键词
生脉活血方
慢性心力衰竭
心房颤动
气虚血瘀型
Shengmai Huoxue Decoction
Chronic heart failure
Atrial fibrillation
Qi deficiency and blood stasis type
